Belgravia Capital International Inc. has appointed Dr. Sam Hanna as Chief Medical Officer of its cannabis dermatology division. Dr. Hanna is a well-recognized Canadian dermatologist with experience in numerous clinical studies for dermatology drugs across North America. The Company announced the appointment of Dr. Hanna on January 10, 2018, as Special Advisor to Belgravia’s wholly owned subsidiary, ICP Organics. Dr. Hanna now assumes leadership for all medical aspects of development of cannabinoid based active pharmaceutical ingredients for dermatological conditions. Dr. Hanna is currently engaged in careful analysis of relevant scientific studies in order to establish developmental approaches. This includes selecting biological markers and drug delivery methodologies. He will also add to the technical team and build out regulatory, and marketing staff and consultants. Dr. Hanna has previously participated in numerous dermatology clinical studies.